Načítá se...
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
OBJECTIVES: To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions. METHODS: This open-label extension study recr...
Uloženo v:
Vydáno v: | Ann Rheum Dis |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
BMJ Publishing Group
2017
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5284338/ https://ncbi.nlm.nih.gov/pubmed/27130908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-208786 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|